Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2017

View Archived Issues

AntriaBio selects lead oral plasma kallikrein inhibitor candidates

InMed reports preclinical results in development of INM-405 for pain

OncBioMune Pharmaceuticals preparing clinical testing of OvcaVax

Lilly and CureVac enter global immune-oncology collaboration to develop mRNA cancer vaccines

Synspira commences phase Ia study of lead candidate for cystic fibrosis

Novartis starts phase I study of NMDA receptor NAM triggering milestone payment to Cadent

NexImmune, The Leukemia & Lymphoma Society to develop immunotherapy for AML

AST-2818 demonstrates antitumoral activity against EGFR T790M mutant NSCLC

Johnson & Johnson reviews highlights of third quarter 2017

Herpes vaccine HSV-529 safe and immunogenic in phase I trial

FDA gives fast track status to Radius Health's elacestrant

AbbVie and Harpoon Therapeutics enter immuno-oncology research collaboration

Mitsubishi Tanabe Pharma's acquisition of NeuroDerm complete

EMA grants orphan drug designation to Conatus' IDN-7314 for primary sclerosing cholangitis

Otsuka submits NDA for nalmefene in Japan

FDA advisory committee recommends approval of once-weekly semaglutide for type 2 diabetes

First-in-human phase I results presented for JNJ-64041757 immunotherapy in lung cancer

Astellas announces a new collaborative research agreement with TB Alliance

FDA approves CAR T therapy Yescarta for adults with relapsed or refractory large B-cell lymphoma

Sage Therapeutics describes novel NMDA receptor modulators

New glucosylceramidase activators identified at Lysosomal Therapeutics

FDA grants priority review to sNDA for Lynparza

AstraZeneca synthesizes novel serine-protein kinase ATM inhibitors

FluGen receives a grant from DOD to test universal flu vaccine against mismatched strains

University of Texas, Immune Sensor divulge new cyclic GMP-AMP synthase inhibitors

Loxo Oncology reports results from committee assessment of larotrectinib dataset

Protalix Biotherapeutics licenses PRX-102 to Chiesi outside U.S.

Vir Biotechnology collaborates with Alnylam and Visterra to develop programs for infectious diseases

Phase II luminespib study in non-small cell lung cancer meets primary endpoint

CEBPA gene novel mutation found to cause congenital lipodystrophy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.